The hemostatic role of factor XI

Area of Science:

• Hematology
• Hemostasis and Thrombosis
• Molecular Biology

Background:

• Coagulation factor XI (FXI) is traditionally linked to the contact pathway of blood coagulation.
• FXI deficiency presents mild bleeding, unlike deficiencies in upstream contact factors, suggesting an independent hemostatic role.
• Predicting bleeding risk in FXI-deficient patients is challenging due to poor correlation with FXI levels or activity.

Purpose of the Study:

• To elucidate the multifaceted roles of coagulation factor XI in both hemostasis and thrombosis.
• To explore FXI's mechanisms in activating coagulation factors and inhibiting TFPI.
• To inform the development of targeted antithrombotic therapies while preserving hemostasis.

Main Methods:

• Review of recent studies on FXI function and clinical data.
• Analysis of FXI's interactions with coagulation factors (FX, FV, FVIII) and TFPI.
• Examination of translational approaches targeting FXI for antithrombotic therapy.

Main Results:

• Activated FXI can activate coagulation factors FX, FV, and FVIII.
• Activated FXI inhibits the anticoagulant tissue factor pathway inhibitor (TFPI).
• FXI is an independent risk factor for deep vein thrombosis, ischemic stroke, and myocardial infarction.

Conclusions:

• FXI possesses distinct procoagulant and antithrombotic activities.
• Understanding FXI's dual role is crucial for predicting bleeding risk and developing targeted therapies.
• FXI inhibition shows promise for preventing thrombosis without compromising hemostasis.